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Tetraspanins regulate key processes in immune cells; however, the function of the
leukocyte-restricted tetraspanin CD53 is unknown. Here we show that CD53 is
essential for lymphocyte recirculation. Lymph nodes of Cd53/mice were smaller
than thoseofwild-typemiceduetoamarkedreduction inBcells anda50%decrease
inTcells. This reducedcellularity reflectedan inabilityofCd53/BandTcells toeffi-
ciently home to lymph nodes, due to the near absence of L-selectin from Cd53/ B
cells and reduced stability of L-selectin on Cd53/ T cells. Further analyses,
including on human lymphocytes, showed that CD53 stabilizes L-selectin surface
expression and may restrain L-selectin shedding via both ADAM17-dependent
andADAM17-independentmechanisms. The disruption in lymphocyte recirculation
in Cd53/mice led to impaired immune responses dependent on antigen delivery
to lymph nodes. Together these findings demonstrate an essential role for CD53 in
lymphocyte trafficking and immunity.
INTRODUCTION
To initiate an adaptive immune response, antigen selects and clonally expands rare antigen-specific lym-
phocytes from a vast repertoire of specificities. The frequency of antigen-specific lymphocytes within the
naive repertoire is minute, estimated in mice to be as low as 15–20 cells per animal (Moon et al., 2007;
Obar et al., 2008), whereas in humans, frequencies can range from 0.6 to 6 cells per million cells (Alanio
et al., 2010; Chu et al., 2009). It is therefore not surprising that the immune system has evolved strategies
to maximize the chances of a successful encounter between antigen and rare antigen-specific lympho-
cytes. To this end, naive lymphocytes constantly patrol throughout the body, recirculating through the
peripheral lymph nodes via interactions within specialized high endothelial venules (HEVs). Then, upon
dwelling in the lymph nodes for 12–24 h, they return to the vasculature via the efferent lymphatics,
enabling them to visit further peripheral lymph nodes (Gowans, 1959; Smith and Ford, 1983; Springer,
1994).
Many of the molecular interactions that govern the egress of naive lymphocytes at HEVs are well un-
derstood, and the key molecule responsible for lymph node homing is the membrane receptor L-se-
lectin (Grailer et al., 2009; Springer, 1994). L-selectin mediates carbohydrate-based interactions with
its HEV-expressed ligands termed peripheral node addressin, thus initiating the tethering and rolling
of naive lymphocytes within HEVs (Streeter et al., 1988) and ultimately leading to stable adhesion and
transmigration of naive lymphocytes into the lymph nodes (Ivetic, 2013). Essential to the control of
lymphocyte trafficking is the tight regulation of L-selectin expression. Upon activation, L-selectin is
rapidly cleaved from the lymphocyte surface predominantly by the metalloprotease ADAM17.
This loss of L-selectin is thought to prevent effector cells from homing to peripheral lymph nodes
thereby indirectly promoting their trafficking to peripheral sites, although this has not yet been
shown experimentally (von Andrian and Mackay, 2000). The molecules that regulate L-selectin shed-
ding are still under investigation and include calmodulin, ERM proteins, and protein kinase C (Ivetic,
2013).iScience 23, 101104, May 22, 2020 ª 2020 The Author(s).
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membranes. There are 34 tetraspanins encoded by the human genome, and these molecules interact with
and organize their partner proteins into signal-transducing microdomains (Rubinstein et al., 2013). In im-
mune cells, the tetraspanin molecular partners include integrins, immunoreceptors, and signaling mole-
cules; thus, tetraspanins control key processes such as immune cell adhesion, migration, and activation
(Jones et al., 2011; Yeung et al., 2018). The functions of many of the immune cell-expressed tetraspanins
are now well documented. For example, in B cells, the tetraspanin CD81 promotes adhesion strengthening
of a4b1 integrin (Feigelson et al., 2003) and additionally serves as a key component of the CD19/CD21 co-
receptor complex that lowers the threshold of B cell signaling (van Zelm et al., 2010). In dendritic cells,
CD81 (Quast et al., 2011) and the tetraspanins CD37 and CD82 (Gartlan et al., 2013; Jones et al., 2016) regu-
late the cytoskeletal rearrangements that drive migration. CD37 is also required for integrin function, both
in neutrophils where it is required for inflammation-associated recruitment (Wee et al., 2015) and in B cells
where it is essential for transducing survival signals during the germinal center reaction (van Spriel et al.,
2012).
By contrast, the function of the pan-leukocyte marker CD53 remains obscure. Despite being one of the first
discovered members of the tetraspanin superfamily (Amiot, 1990), CD53 has not been robustly examined,
with a range of in vitro studies weakly suggesting a variety of roles. Cross-linking CD53 at the cell surface
can lead to leukocyte activation (Bell et al., 1992; Bosca and Lazo, 1994; Cao et al., 1997; Lagaudriere-Ges-
bert et al., 1997; Lazo et al., 1997), a result perhaps explained by more recent sophisticated analyses that
demonstrate a role for CD53 in PKC signaling (Zuidscherwoude et al., 2017). Transfection and expression
studies have suggested a role in the regulation of apoptosis (Kim et al., 2004; Yunta and Lazo, 2003) and
T cell development (Puls et al., 2002), whereas genetic and phenotypic analyses suggest a role for muta-
tions in CD53 in immunodeficiency (Mollinedo et al., 1997) or various inflammatory disorders including
arthritis, asthma, and Sjo¨gren’s syndrome (Bos et al., 2010; Khuder et al., 2015; Lee et al., 2013; Peder-
sen-Lane et al., 2007; Xu et al., 2015). Here, we analyze CD53 function using a reverse genetics approach.
The data show a striking phenotype as CD53-deficient lymphocytes home poorly to lymph nodes, an effect
associated with marked reductions in L-selectin expression and stability of these cells. Thus, we demon-
strate that CD53 is a key player in the regulation of lymphocyte recirculation.RESULTS AND DISCUSSION
The Cellularity of Cd53/ Peripheral Lymph Nodes Is Reduced due to a Striking Defect in
Lymphocyte Homing
To investigate the function of the tetraspanin CD53, we first analyzed the lymphoid organs of Cd53/
mice. No difference in the gross appearance or mass of spleens was observed; however, Cd53/ periph-
eral lymph nodes (pLN; inguinal and brachial) were smaller in appearance and weighed less than their wild-
type (WT) counterparts (Figure 1A). CD53 ablation had no significant effect on the cellularity of the bone
marrow, thymus, blood, spleen, and mesenteric lymph nodes. However, pLN from Cd53/ mice showed
a striking defect in cellularity with a reduction of approximately 60% compared with WT (Figure 1B). This
was not a delay in development, as the cellularity in the spleens of WT and Cd53/ mice was identical
over time, whereas the pLN of Cd53/ mice remained smaller even in 52-week-old mice (Figure 1C). To
further analyze the impaired cellularity of Cd53/ pLN, cells from pLN and spleen were analyzed by
flow cytometry and lymphocytes were enumerated. Dot plot analyses showed a slight increase in the fre-
quency of T cells and a striking reduction in the frequency of B cells in the pLN of Cd53/mice (Figure 1D).
Quantification of absolute B cell numbers confirmed this reduction (Figure 1F). The number of pLN B cells in
Cd53/mice was only14% of that in WT. For pLN T cells, quantification revealed a smaller,50% deficit,
applying to both the CD4+ and CD8+ lineages. In parallel we observed a marginal, although significant,
increase in the number of T cells in the spleen (Figure 1E).
Given the normal cellularity of the spleen and other lymphoid organs, and the documented roles of tetra-
spanins in regulating cell migration and leukocyte trafficking (Yeung et al., 2018), we reasoned that a defect
in lymphocyte recirculation may underlie the phenotype of poor lymph node cellularity. We therefore eval-
uated whether CD53 ablation affected lymphocyte homing to lymph nodes. First, to investigate whether
CD53 ablation had an effect on lymph node architecture or on HEVs, homing assays were performed where
WT splenocytes were labeled with carboxyfluorescein succinimidyl ester (CFSE) and adoptively transferred
into WT and Cd53/mice (Figure 2A). Flow cytometric analysis was used to identify the relative frequency
of adoptively transferred splenocytes in each organ (Figure 2B), and to distinguish B and T cells (data not2 iScience 23, 101104, May 22, 2020
Figure 1. CD53 Ablation Reduces the Cellularity of Peripheral Lymph Nodes
Lymphoid organs from 10-week-old WT and Cd53/ mice were harvested and analyzed.
(A) Representative images and mass of WT and Cd53/ spleens and peripheral lymph nodes (pLN).
(B) Total cell numbers of lymphoid organs (BM, bone marrow; thymus; blood; spleen; mLN, mesenteric lymph nodes; and
pLN).
(C) Total cell number of spleens and pLN as determined at time points from 4 to 52 weeks.
(D) Flow cytometry analyses of spleen and pLN identifying B (B220+) and T (CD3+) cells and CD4 + and CD8+ T cell
populations.
(E and F) Quantification of (E) T cell and (F) B cell populations in spleen and pLN.
Data are represented as meanG SEM, n = 6–17 mice per group pooled from 2–5 independent experiments, *p% 0.05,
**p% 0.01, ***p% 0.001, ****p% 0.0001, Student’s two-tailed unpaired t test.
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Figure 2. CD53 Is Required for Efficient Lymphocyte Homing to Lymph Nodes
(A–D) WT splenocytes were labeled with CFSE and injected intravenously (i.v.) into WT or Cd53/ recipient mice. Forty-eight hours later lymphoid organs
were harvested and analyzed for CFSE+ cells using flow cytometry. (A) Schematic, illustrating experimental design. (B) Representative flow cytometry
illustrating the identification of transferred CFSE+ cells in the spleens and pLN of recipient mice. (C and D) Enumeration of CD19+CFSE+ adoptively
transferred B cells (C) and CD3+CFSE+ adoptively transferred T cells (D) in the lymphoid organs of recipient mice. Data are from 8 mice per group pooled
from 2 independent experiments.
(E–I) WT andCd53/B or T cells were purified, CFSE-labeled, and co-injected i.v. intoWT recipient mice together with an internal control of WT (B or T) cells
differentially labeled with Cell Tracker 670. (E) Schematic, illustrating experimental design. (F and H) Representative flow cytometry comparing the homing of
WT-Cell tracker 670+, WT-CFSE+, and Cd53/CFSE+ CD19+ B cells (F) and CD3+ T cells (H) to peripheral lymph nodes. (G and I) Homing indices of
transferred B cells (G) and T cells (I) to each organ.
Data are represented as mean + SEM, 8 mice per group pooled from 2 independent experiments, *p% 0.05, ***p% 0.001, Student’s two-tailed unpaired t
test (C and D) or Mann-Whitney test (G and I).
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WT B and T cells to home to the spleens of Cd53/mice, homing to peripheral and mesenteric lymph no-
des was normal (Figures 2C and 2D). Thus, the reduced cellularity of Cd53/ pLN is likely a phenotype
intrinsic to Cd53/ lymphocytes. Next, we investigated the homing capacity of Cd53/ lymphocytes.
WT and Cd53/ B or T cells were purified, labeled with CFSE, and co-injected into WT recipient mice
together with an internal control of WT (B or T) cells differentially labeled with Cell Tracker 670 (Figure 2E).
After 48 h immune organs were harvested and homing analyzed by flow cytometry (Figures 2F and 2H).
Quantification was calculated using a homing index (Arbones et al., 1994) where the ratio of CFSE+ test
cells to Cell Tracker 670+ internal control cells in the initial injection mixture and also within each organ4 iScience 23, 101104, May 22, 2020
Figure 3. CD53 Stabilizes L-Selectin Expression on the Lymphocyte Surface
(A and B) (A) Representative flow cytometry histograms (splenic B cells), and quantification of L-selectin protein
expression (B; mean fluorescent intensity, MFI) on B220+WT andCd53/B cells harvested from spleen, peripheral lymph
nodes (pLN), and mesenteric lymph nodes (mLN). Data are represented as mean + SEM, 3 mice per group, representative
ofR3 independent experiments.
(C) Expression of WT human L-selectin on WT and hCd53/ human BJAB cells.
(D and E) (D) Representative flow cytometry (splenic T cells) and quantification (E, MFI) of L-selectin expression on CD3+
WT and Cd53/ T cells harvested from spleen and pLNs from 10-week-old mice. Data are represented as mean + SEM,
10 mice per group pooled from 2 independent experiments.
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Figure 3. Continued
(F) Quantification of L-selectin expression (MFI) on CD3+ T cells harvested from aged (52-week-old) WT and Cd53/
mice. Data are represented as mean + SEM, n = 6 mice per group representative of 2 independent experiments.
(G–J) WT and Cd53/ splenocytes were cultured at 37C with or without the broad metalloprotease inhibitor GM6001
(GM; 100mM). Flow cytometry was used to distinguish B (B220+) and T (CD3+) cells and monitor L-selectin expression. (G
and I) Representative flow cytometry histograms displaying L-selectin expression on B cells (G) and T cells (I) after 2 h at
37C. (H and J) The kinetics of L-selectin expression on cultured B (H) and T (J) cells relative to cells held at 4C.
(K–N) Purified WT and Cd53/ T cells were stimulated with PMA (50 ng/mL) to induce shedding in the presence or
absence of metalloprotease inhibitors. (K) Representative histograms illustrating L-selectin expression in unstimulated
(unstim), PMA stimulated (50), and PMA stimulated in the presence of the metalloprotease inhibitor GM6001 (PMA 50 +
GM). (L) The kinetics of L-selectin surface expression (relative to unstimulated cells) and (M) amount of soluble L-selectin
shed into supernatants of WT and Cd53/ T cells stimulated with PMA. (N) The percentage of L-selectin expression
(relative to unstimulated cells) remaining after 150 PMA stimulation in the presence or absence of the metalloprotease
inhibitors GM6001 (100 mM, GM), GI 254023X (20 mM, GI ), TAPI-1 (200 mM), and A9 (5 mM).
Data are represented as meanG SEM, n = 6–7mice per group pooled from 3 independent experiments, *p% 0.05, **p%
0.01, ***p% 0.001, ****p% 0.0001, Student’s two-tailed unpaired t test (B, C, E, F, M, N) or Mann-Whitney test (H, J, L).
See also Figures S1–S3.
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Although Cd53/ B cells were able to localize to blood normally, they preferentially localized to the
spleen, whereas homing to the pLN was almost completely abrogated (Figure 2G). There was also a signif-
icant reduction of B cell homing to the mesenteric lymph nodes (25% of WT; Figure 2G). A similar dysregu-
lation inCd53/ T cell lymph node homing was observed, although the phenotype was not as pronounced
(Figure 2H). Cd53/ T cells also preferentially localized to the spleen, whereas homing to both the pLN
and mLN was poor (Figure 2I). In conclusion, CD53 ablation induces reduced cellularity in pLN due to a se-
vere defect in lymphocyte homing, with the phenotype more pronounced in B cells than in T cells.
CD53 Ablation Impairs Expression of L-Selectin on Lymphocytes
Given that CD53 ablation induces a defect in lymph node homing, we hypothesized that CD53 might regu-
late the key lymph node homing receptor, L-selectin. We therefore analyzed L-selectin expression by flow
cytometry and identified that the residual B cell (B220+) population found in Cd53/ pLN had significantly
reduced expression of L-selectin protein (Figure 3A). Indeed, across spleen, pLN, andmLN there was a ma-
jor reduction in the surface expression of L-selectin on Cd53/ B cells of up to two orders of magnitude
(Figure 3B). To investigate whether our findings extended to human cells, we generated human Cd53/
B cell lines (BJAB) using CRISPR/Cas9 technology. We observed impaired cell surface L-selectin expression
in two independent human Cd53/ B cell lines, in accord with our mouse data (Figure 3C). In comparison,
the expression of L-selectin on Cd53/ T cells revealed a small, but significant, reduction of L-selectin
expression of 8% and 20% in splenic and pLN T cells, respectively (Figures 3D and 3E). This diminution
of L-selectin expression was exaggerated in T cells from aged mice where there was an approximately
60% reduction of L-selectin expression (Figure 3F).
To investigate the mechanism by which CD53 regulates L-selectin we first analyzed mRNA expression in
lymphocytes and could detect no reduction in L-selectin mRNA expression associated with CD53 ablation
in both resting and activated cells (Figure S1). L-selectin is cleaved from the surface of lymphocytes by met-
alloproteases. In activated lymphocytes, the predominant metalloprotease that drives shedding is
ADAM17, whereas the metalloprotease responsible for the constitutive shedding observed in unactivated
lymphocytes has not been identified (Mohammed et al., 2019). There is growing evidence that tetraspanins
can regulate this enzyme family. For example, the TspanC8 subgroup of tetraspanins molecularly interacts
with and regulates the activity of ADAM10 (Matthews et al., 2017). We therefore investigated whether CD53
regulates L-selectin expression via effects on metalloproteases. We first examined L-selectin expression on
unstimulatedWT andCd53/ B cells incubated at 37C in the presence of the broad-spectrummatrix met-
alloprotease inhibitor, GM6001. Incubation of WT B cells at 37C induced a spontaneous reduction in L-se-
lectin expression, which was completely inhibited by GM6001 (Figure 3H). L-selectin expression on
Cd53/ B cells was much lower than on WT cells, and although incubation of Cd53/ B cells with
GM6001 (Figures 3G and 3H) increased L-selectin expression more than 3-fold, it could not restore expres-
sion to WT levels. This suggests that the reduced L-selectin expression on Cd53/ B cells may be only
partially accounted for by metalloproteinase activity. Incubation of WT T cells at 37C also induced a spon-
taneous reduction in L-selectin expression, and this reduction was significantly exaggerated in Cd53/
T cells (Figures 3I and 3J). In marked contrast to B cells, the reduced levels of L-selectin on CD53/6 iScience 23, 101104, May 22, 2020
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levels of L-selectin in CD53/ T cells are largely due to spontaneous shedding. To study the impact of
CD53 on ADAM-17-dependent L-selectin shedding in T cells, we used phorbol 12-myrsitate 13-acetate
(PMA) activation. We observed that the reduction of L-selectin surface expression from Cd53/ T cells
was significantly accelerated (Figures 3K and 3L), with an increase in shed soluble L-selectin levels observed
in the supernatant of Cd53/ when compared with WT cells (Figure 3M). GM6001 and TAPI-1 (another
small molecule metalloprotease inhibitor that can inhibit ADAM17) were able to largely prevent the loss
of L-selectin surface expression in WT T cells and maintain L-selectin at 70% of unstimulated levels,
whereas these inhibitors were all less effective in PMA-stimulated Cd53/ T cells and could only maintain
L-selectin expression at 25% of unstimulated levels. Similarly, the ADAM-17 blocking monoclonal anti-
body A9 (Kwok et al., 2014) was also less effective in inhibiting PMA-induced reduction of L-selectin surface
expression on Cd53/ T cells compared with WT T cells. The ADAM-10-specific inhibitor GI254023X had
no effect in these assays (Figure 3N), demonstrating that ADAM10 did not substitute for ADAM-17 in PMA-
activated T cells as shown here and by others (Mohammed et al., 2019).
In summary, treatment with metalloprotease inhibitors: increases the expression of L-selectin onCd53/ B
cells (Figures 3G and 3H), prevents the instability of L-selectin expression onCd53/ T cells (Figures 3I and
3J), and partially restores L-selectin expression in PMA-treated Cd53/ T cells (Figures 3K and 3N). Taken
with the exaggerated accumulation of L-selectin in the supernatant of PMA-activated Cd53/ T cells (at
early time points, Figure 3M), the data support a role for CD53 in inhibiting metalloprotease-mediated
shedding of L-selectin from the lymphocyte surface. However, analyses of ADAM17-deficient cells and
mice indicate that there are additional mechanisms of regulating L-selectin expression and shedding
that are independent of ADAM17 (Le Gall et al., 2009; Walcheck et al., 2003; Wang et al., 2010). Given
that metalloprotease inhibitors, or a blocking antibody targeting ADAM17, diminished but did not abro-
gate the excessive loss of L-selectin induced by PMA stimulation on the surface of Cd53/ T cells, our
data indicate that CD53 also inhibits ADAM17-independent mechanisms, some of which may be metallo-
protease-independent. One possibility is that CD53might have a role in L-selectin trafficking. We therefore
distinguished intracellular and extracellular L-selectin expression in resting and PMA-activated permeabi-
lized lymphocytes, but could detect no evidence of an intracellular accumulation of L-selectin in Cd53/
cells, arguing against a role for CD53 in either trafficking L-selectin to the cell surface or internalizing L-se-
lectin after activation (Figure S2). Taken together, we conclude that CD53 is required to stabilize L-selectin
expression at the lymphocyte surface, and further studies will be required to identify the additional metal-
loprotease(s) or mechanisms responsible.
Cd53/ B cells express very low levels of L-selectin, and consequently are unable to home to peripheral lymph
nodes. By contrast, L-selectin expression inCd53/ T cells is only marginally reduced (Figure 3) but is unstable,
as shown by the relatively poor expression of L-selectin on T cells from agedCd53/mice (Figure 3F), and the
spontaneous loss of L-selectin surface expression induced by incubation of Cd53/ T cells at 37C (Figures 3I
and 3J). This L-selectin instability likely explains the impairment of Cd53/ T cell homing to peripheral lymph
nodes, althoughwecannot rule out othermechanisms such as a defect in signal transduction. In linewith this, we
have recently shown that CD53 can directly interact with PKC and is required for PKC activation in B cells (Zuid-
scherwoude et al., 2017), suggesting thatCD53 interacts with PKC and L-selectin in the samemolecular complex
(Kilian et al., 2004). The difference in the biology of CD53 ablation on B and T cells likely reflects the ratio of
CD53:L-selectin expression on the two cell types. CD53 is expressed at higher levels on B cells than on
T cells (Tomlinson et al., 1995), whereas T cells express approximately 50%more L-selectin than do B cells (Gau-
guet et al., 2004). Thus, on B cells there is relatively more CD53 available to stabilize lower levels of L-selectin
(and vice versa). Alternatively, there may be another tetraspanin that compensates for CD53 on T cells, but is
not expressed in B cells. One candidate is CD9, as in vitro studies have shown that it can inhibit ADAM17-medi-
ated shedding of another substrate, tumor necrosis factor (Gutierrez-Lopez et al., 2011), and it is strongly ex-
pressed on T cells but not on most B cells. However, we think this is unlikely as lymph node cellularity in
Cd9/ mice is normal (Iwasaki et al., 2013) and CD53 ablation does not significantly affect CD9 expression
in either Cd53/ T cells or hCd53/ BJAB cells (Figure S3).Defective Lymphocyte Homing Delays Adaptive Immune Responses when Antigen Is
Delivered to Lymph Nodes
To examine whether the impairment of lymphocyte recirculation in Cd53/ mice had an effect on
immunity, mice were first challenged with classical model antigens (namely the type I T-independentiScience 23, 101104, May 22, 2020 7
Figure 4. Adaptive Immune Responses in Cd53/ Mice Are Delayed when Antigen Is Delivered to Lymph Nodes
(A–F) WT and Cd53/ mice were immunized intraperitoneally (IP; A, C, and E) or intradermally (ID; B, D, and F) with (A and B) 50 mg NP-FICOLL, (C and D)
50 mg NP-LPS, or (E and F) 50 mg NP-KLH. NP-specific antibody responses were determined by ELISA for IgM, IgG1, IgG2b, and IgG3. Data are represented
as mean G SEM, 9–17 mice per group pooled from 2 independent experiments.
(G) Autoimmune encephalomyelitis was induced in WT and Cd53/ mice where mice were immunized subcutaneously with MOG peptide. Disease
progression was measured daily and expressed as a clinical score as meanG SEM, 10 mice per group from 2 independent experiments. *p% 0.05, **p%
0.01, ***p% 0.001, ****p% 0.0001, Student’s two-tailed unpaired t test (A–F) or two-way ANOVA (G).
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KLH) to induce humoral responses. Antibody responses ofCd53/mice were largely normal to all antigens
administered systemically (intraperitoneally, Figures 4A, 4C, and 4E). Similarly, responses to intradermal
NP-LPS were also normal (Figure 4D). Collectively, these data indicate that CD53 ablation does not signif-
icantly affect the germinal center reaction, antigen presentation, T cell help, or the ability of B cells to pro-
liferate and generate plasma cells. However, when NP-KLH was delivered to lymph nodes via intradermal
injection,Cd53/ antibody responses were significantly delayed (Figure 4F). Similarly, with regard to T cell
responses, the clinical responses ofCd53/mice in experimental autoimmune encephalomyelitis, a T cell-
dependent model of autoimmunity initiated by subcutaneous immunization with MOG peptide, were also
delayed (Figure 4G). We conclude that when antigen is delivered to the lymph nodes of Cd53/ mice
adaptive immune responses are delayed. This pattern of normal responses to systemically administered
antigen versus delayed immunity when antigen is delivered to pLN via the subcutaneous and intradermal
routes is strikingly similar to that reported for L-selectin knockout mice (Catalina et al., 1996; Steeber et al.,
1996). This illustrates the importance of lymphocyte recirculation in immunity; presumably, the poor cellu-
larity of lymphocytes, particularly B cells, in the lymph node delays immune responses. The one exception
here was the exaggerated immune responses of Cd53/mice to NP-FICOLL when administered intrader-
mally (Figure 4B). It is difficult to explain this result, although this was also observed in L-selectin-deficient
mice (Steeber et al., 1996). T-independent type II antigen responses arise in themarginal zone of the spleen8 iScience 23, 101104, May 22, 2020
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nuesa and Chang, 2013). The numbers of these cell populations are normal in Cd53/ mice, and we
can only speculate either that a deficiency in the CD53/L-selectin axis induces subtle changes in trafficking
or localization in these populations or that L-selectin expressed in these populations has a hitherto undis-
covered function in negatively regulating type II T-independent responses.
In summary, these analyses identify an indispensable role for CD53 in maintaining lymph node cellularity
(Figure 1). A very recent analysis of Cd53/ mice attributed the poor lymph node cellularity to defects
in B cell development and showed evidence that CD53 is required for optimal interleukin-7R signaling
(Greenberg et al., 2020). Here we identify another mechanism: CD53 is required for lymphocyte homing
to lymph nodes (Figure 2). The central role of L-selectin in lymph node homing is well established. However,
the molecular mechanisms underlying L-selectin stabilization at the plasma membrane are less well under-
stood. This article demonstrates that L-selectin expression on lymphocytes is tightly controlled by the
leukocyte-specific tetraspanin CD53 and that CD53, at least partially, mediates this effect by inhibiting
L-selectin shedding (Figure 3). Consequently, CD53 is required for efficient and timely immune responses
(Figure 4).
Limitations of This Study
This article analyzes the development and immune responses of Cd53/mice and the immunobiology of
Cd53/ lymphocytes in in vivo and in vitro assays. The molecular interactions of CD53 and themechanisms
by which it stabilizes L-selectin surface expression await further analyses.
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Figure S1. CD53 ablation does not decrease L-selectin mRNA expression, Related to 
Figure 3. Relative L-selectin mRNA expression in resting (A) and activated (B) WT and 
Cd53-/- T and B cells. Data are represented as mean + SEM, 6 mice per group pooled from 2-
3 independent experiments, * p ≤ 0.05, Student’s two tailed t-test. 
 
  
 
 
Figure S2. CD53 ablation does not lead to an accumulation of intracellular L-selectin, 
Related to Figure 3. (A) Representative flow cytometry histograms depicting intracellular and 
surface L-selectin expression in WT and Cd53-/- T and B cells. Quantification (mean 
fluorescent intensity, MFI) of surface (B and D) and intracellular (C and E) L-selectin 
expression in WT and Cd53-/- T cells (B and C) and B cells (D and E), as determined by flow 
cytometry with and without stimulation by PMA (5 minutes). Data are represented as mean + 
SEM, 5 mice per group, * p ≤ 0.05, **** p ≤ 0.0001, one-way ANOVA. 
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Figure S3. CD53 ablation has minimal effect on CD9 membrane expression, Related to 
Figure 3. (A) Quantification (mean fluorescent intensity, MFI) of CD9 expression on WT and 
Cd53-/- mouse T cells as determined by flow cytometry. Data are represented as mean + SEM, 
3 mice per group. (B) Representative flow cytometry histograms illustrating human CD9 
expression on WT and hCd53-/- human BJAB cells. 
  
Transparent Methods 
 
Mice 
 
The generation of Cd53-/- mice has been recently described (Zuidscherwoude et al., 2017). Both 
Cd53-/- and C57BL/6J (wild-type, WT) mice were bred at the Monash Animal Research 
Platform (MARP), or Animal Research Laboratories (ARL) at Monash University (Clayton 
campus, Australia) or the Precinct Animal Centre (PAC) at the Alfred Research Alliance 
(formerly the Alfred Medical and Research Education Precinct (AMREP)) Melbourne, under 
specific-pathogen free conditions. All mice used for experimentation were between 4-12 weeks 
of age (or as indicated in text) and C57BL/6J age- and sex-matched mice were used as controls. 
The AMREP AS Animal Ethics Committee approved all experiments.  
 
Lymphoid organ single cell suspensions 
Lymphoid organs (including spleen, thymus, peripheral (inguinal and brachial) and mesenteric 
lymph nodes) were aseptically removed from WT and Cd53-/- mice. Blood (500 µL, collected 
by cardiac puncture) was placed into an equal volume of Alsever’s solution to prevent 
coagulation. Single cell suspensions were prepared by disruption of organs in appropriate 
buffer. Bone marrow was flushed from the femur and tibia of WT and Cd53-/- mice using 25G 
needles. Erythrocytes in spleens, bone marrow and blood were lysed in ice-cold ACK lysis 
buffer. All suspensions were filtered through 70 µm strainers to remove cellular debris and 
washed. Viable cells were enumerated on a haemocytometer using trypan blue exclusion. 
 
Flow cytometry 
Cells were labelled with antibodies against a range of surface markers conjugated to a range of 
fluorochromes as follows: anti-B220 FITC* or APC Cy7 (RA3-6B2), anti-CD3 FITC or Cy5* 
(KT31.1), anti-CD4 Pacific Blue (RM4-5), anti-CD8 PE or APC Cy7 (53-6.7), anti-CD19 PE 
or eFluor450 (1D3), anti-CD53* (OX-79) and anti-L-selectin PE or PE Cy7 (MEL-14). 
Antibodies with an asterisk were purified and conjugated in house, all others were purchased 
from BD Pharmingen (San Diego, CA) or eBioscience (CA, USA).  Antibodies were diluted 
to the appropriate titrated concentration in appropriate buffer, and cells stained on ice for 30 
min. Cells were washed and resuspended in buffer containing 0.2% v/v propidium iodide prior 
to acquisition on a BD FACSCalibur, LSR II or LSRFortessa (BD Biosciences). Cells were 
analysed using FlowJo Software (TreeStar Inc., OR, USA) following exclusion of doublets and 
propidium iodide-positive cells. For assessment of surface and intracellular L-selectin, non-
permeabilised lymph node cells were first stained for surface L-selectin using PE-conjugated 
anti-L-selectin (clone MEL-14) at a concentration (8 µg /ml) determined in pilot experiments 
to minimize any further staining achieved by subsequent exposure to anti-L-selectin-FITC 
(data not shown). Cells were subsequently washed, fixed/permeabilized (BD 
Cytofix/Cytoperm, BD Biosciences Pharmingen) and stained for intracellular L-selectin using 
FITC-conjugated anti-L-selectin (5 µg/ml).  Surface and intracellular L-selectin levels were 
determined via flow cytometric analysis, identifying T cells as TCR beta chain+ cells (clone 
H57-597, conjugated to APC), and B cells as CD19+ cells (clone 1D3, conjugated to BV711). 
 
B and T cell isolation 
B cells were isolated by negative selection from the spleens of WT and Cd53-/- mice using the 
Dynabeads Mouse CD43 (Untouched B cells) kit (Life Technologies, CA, USA) according to 
the manufacturer’s instructions.  Negative selection by magnetic bead depletion was used for 
T cell isolation as previously described (Sheng et al., 2009).  
 
Homing Assays  
WT splenocyte homing assay.	 Single cell suspensions of WT spleens were prepared as 
described above. Splenocytes were labeled with 0.5 μM CFSE (10 mins, 37°C; Life 
Technologies, CA, USA). 3x107 splenocytes in 100 μL PBS were injected i.v. into WT and 
Cd53-/- mice. Spleens, peripheral (inguinal and brachial) LNs, mesenteric LNs and blood were 
harvested 48 h later and single cell suspensions analysed by flow cytometry for the presence 
of CFSE+ splenocytes, including CFSE+ CD19+ B cells and CFSE+ CD3+ T cells. Absolute 
CFSE+ cell number in each organ was calculated based on frequencies of CFSE+ cells and 
organ cell counts.  
B and T cell homing assays.  B and T cells from WT and Cd53-/-
 
mice were isolated and labelled 
with CFSE as above. WT cells were also labelled with 1 μM Cell Proliferation Dye eFluor670 
(referred to in this article as Cell Tracker 670; 10 min, 37°C; eBioscience, CA, USA) for use 
as an internal control. 107 WT or Cd53-/- CFSE-labelled B or T cells were mixed in equal 
numbers with Cell Tracker 670-labelled WT B or T cells and injected i.v. into WT mice in 100 
μL PBS. The injected cell mixture was analysed by flow cytometry to determine the ratio of 
fluorescently-labelled cells in the starting preparation. Lymphoid organs were harvested after 
48 h and analysed by flow cytometry for fluorescently-labelled CD3+ T cells or CD19+ B cells. 
Homing indices were calculated according to the following formula:  
Homing index = (Sample:Internal control)organ / (Sample:Internal control)injected  (Arbones et 
al., 1994). 
Gene expression by real-time quantitative PCR (qPCR) 
Purified B and T cells were activated for 18 h with 10 µg/mL of LPS (from E. coli K12; 
InvivoGen, CA, USA) or 10 µg/mL immobilised anti-CD3 plus 1 µg/mL soluble anti-CD28, 
respectively. Activated cells were analysed by flow cytometry for the upregulation of CD69 
and/or CD25. RNA was isolated from purified B and T cells (naïve or activated) using the spin 
purification protocol from the SV Total RNA Isolation System (Promega, WI, USA) and 
converted to cDNA through the use of an RNA to cDNA kit according to manufacturer 
instructions (Life Technologies, CA, USA). Levels of mouse L-selectin and 18S mRNA were 
measured using predesigned Taqman® Gene Expression Assays (Catalog Mm_0041291_m1 
and Mm_03928990_g1; Life Technologies, CA, USA). qPCR was performed according to 
manufacturer instructions in an ABI Prism® 7900HT Sequence Detection System (Life 
Technologies).   
 
L-selectin shedding assays  
2-2.5x106 cells/well of purified wild-type and Cd53-/- mouse T lymphocytes were activated at 
37°C with 50 ng/mL (80 nM) PMA in 0.5% BSA/RPMI at designated time points (2.5, 5, 15, 
and 30 min) to induce L-selectin shedding from the cell surface. When required, cells were 
pre-incubated at 37°C with inhibitors for 10 min prior to the addition of PMA. A broad 
spectrum metalloprotease inhibitor GM6001 (Tocris Bioscience, Bristol, UK), TAPI-1 (an 
inhibitor of ADAM17, Tocris Bioscience), ADAM17-specific inhibitory antibody A9(B8) 
(Kwok et al., 2014), and GI254023X (a potent inhibitor of ADAM10, Tocris Bioscience) were 
added at final concentrations of 100 μM, 20 μM, 200 nM or 5 μM respectively. An unstimulated 
control (no PMA) was included, where 0.5% BSA/RPMI was added to cells instead. All 
reactions were stopped by placing wells on ice. Cells were then centrifuged at 1,800 rpm for 5 
min at 4°C. The supernatant was harvested for ELISA experiments, and cells were resuspended 
in FACS buffer. 5x105 cells were stained with anti-CD3 FITC, and anti-L-selectin PE. Levels 
of L-selectin surface expression were determined by flow cytometry on the FACSCalibur (BD 
Biosciences) or the LSRFortessa (BD Biosciences). A sandwich ELISA was used to determine 
soluble L-selectin levels in supernatants from activated T and B cells. Wells were coated with 
anti-mouse L-selectin (clone 95226; R&D Systems, MN, USA) and L-selectin detected by 
biotinylated anti-mouse L-selectin (clone 95218; R&D Systems, MN, USA). Recombinant 
mouse L-selectin/CD62L Fc Chimera was used as a standard in all assays (R&D Systems, MN, 
USA). Streptavidin-HRP, TMB (Life Technologies, CA, USA) and 1M HCl were used for 
detection. OD was determined at 450 nm (Multiskan Go plate reader, ThermoFisher Scientific). 
For long-term assays to measure spontaneous L-selectin shedding without PMA activation, 
2x106 cells were incubated as above and for 1, 2 or 3 h. Cells were harvested and stained with 
antibodies to L-selectin, CD3 or B220 as required, prior to acquisition on a flow cytometer.  
 
Analysis of human Cd53-/- B cells 
 
Monoclonal and polyclonal Cd53-deficient human BJAB cells were generated by CRISPR-
Cas9 technology as previously described (Zuidscherwoude et al., 2017). DNA electroporation 
of WT and CD53-deficient cells was performed with the Neon® Transfection System 
MPK5000 (Thermo Fisher Scientific, MA, USA). Per transfection, 4.8 × 106 cells were washed 
in PBS and resuspended in 120 µL resuspension buffer R and mixed with 0.5 µg pmaxGFP™ 
(Cell Line Optimization Solution Box; Lonza, Basel, CH) and 1.5 µg L-selectin DNA. A 
volume of 100 µL was transferred to a Neon® Electroporation Tube in a 100 µL Neon® Tip 
(Neon® Transfection System 100 µL Kit; MPK10096, Invitrogen). A single electroporation 
pulse of 1350V for 40 ms was given. After transfection, cell suspensions were resuspended in 
3 mL RPMI without antibiotics and cultured overnight at 37oC and 5% CO2. 
 
Transfected cells were kept at optimal densities for 48 h. Three groups of 2×105 cells per 
transfected and untransfected controls were washed in PBS and resuspended in either PBA (1x 
PBS, 1% BSA, 0.05% NaN3), 1µg/mL mouse IgG1 isotype (clone MOPC-21; BioLegend, SD, 
USA) or 1 µg/mL mouse anti-human anti-L-selectin (clone DREG56; Novus, Manchester, UK) 
and incubated on ice for 30 min. Cells were washed in PBS and resuspended in either PBA 
(PBS), or goat anti-mouse IgG1 Alexa Fluor® 647 (Invitrogen, MA, USA) and incubated in the 
dark on ice for 30 min. Cells were then washed in PBS and resuspended in 150 µL PBA and 
analyzed on MACSQuant® Analyzer 10 flow cytometer (Milteny Biotec, Bergisch Gladbach, 
DE). 
Induction and measurement of immune responses 
Mice were immunised intraperitoneally (i.p.) or intradermally (i.d.) at the base of the tail with 
100 μg NP(25-28)-KLH (Biosearch Technologies, Novato, CA) precipitated in alum (10% 
w/v) as an adjuvant (T-cell dependent responses) or with 50 μg NP(0.6)-LPS or NP(40)-
AECM-FICOLL in PBS (Biosearch Technologies, Novato, CA) (T-cell independent 
responses). A pre-bleed (submandibular) was taken before immunisation and submandibular 
bleeds were taken weekly from immunised mice. ELISAs to determine isotype specific 
antibody responses against NP were performed as previously described (van Spriel et al., 
2009).  
EAE was induced by MOG35-55 immunisation following a standard protocol (Chan et al., 
1997). Briefly, mice were immunised subcutaneously in each flank with 100 μg MOG35-55 
(GL Biochem, Shanghai, China) emulsified in CFA supplemented with 4 mg/mL of 
Mycobacterium tuberculosis H37Ra (DICO laboratories, USA) and also injected on the same 
day i.p. with 350 ng/mouse Pertussis toxin (List Biological laboratories, USA) in PBS. Forty-
eight hours later mice were re-injected with 350 ng/mouse Pertussis toxin i.p. Mice were 
monitored daily for weight loss and clinical signs of EAE. Clinical scores were assigned 
according to the following: 0, no disease; 1, tail weakness; 2, tail paralysis and hind limb 
weakness; 3, hind limb paralysis; 4, hind and forelimb paralysis; 5 death. For ethical reasons 
mice were culled when a clinical score of 3 was reached.  
Statistical analysis  
The student’s two tailed t-test, or Mann-Whitney test, or 2-way ANOVA (for EAE) was used 
to for statistical comparisons between data sets. GraphPad Prism 6 software (CA, USA) was 
used for statistical analysis.  
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